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Abstract
Background: Lung cancer causes the highest rate of cancer-related deaths both in men and women. As many
current treatment modalities are inadequate in increasing patient survival, new therapeutic strategies are required.
TNF-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in tumor cells but not in normal cells,
prompting its current evaluation in a number of clinical trials. The successful therapeutic employment of TRAIL is
restricted by the fact that many tumor cells are resistant to TRAIL. The goal of the present study was to test a
novel combinatorial gene therapy modality involving adenoviral delivery of TRAIL (Ad5hTRAIL) and IKK inhibition
(AdIKKbKA) to overcome TRAIL resistance in lung cancer cells.
Methods: Fluorescent microscopy and flow cytometry were used to detect optimum doses of adenovirus vectors
to transduce lung cancer cells. Cell viability was assessed via a live/dead cell viability assay. Luciferase assays were
employed to monitor cellular NF-B activity. Apoptosis was confirmed using Annexin V binding.
Results: Neither Ad5hTRAIL nor AdIKKbKA infection alone induced apoptosis in A549 lung cancer cells, but the
combined use of Ad5hTRAIL and AdIKKbKA significantly increased the amount of A549 apoptosis. Luciferase assays
demonstrated that both endogenous and TRAIL-induced NF-B activity was down-regulated by AdIKKbKA
expression.
Conclusions: Combination treatment with Ad5hTRAIL and AdIKKbKA induced significant apoptosis of TRAIL-
resistant A549 cells, suggesting that dual gene therapy strategy involving exogenous TRAIL gene expression with
concurrent IKK inhibition may be a promising novel gene therapy modality to treat lung cancer.
Backround
Lung cancer is the leading cause of cancer mortality in
the world (31% for men and 26% for women of all can-
cer deaths) [1]. Despite the use of conventional multi-
modal treatment methods (chemotherapy, radiation, and
surgery), the overall survival rate from lung cancer has
improved little, with <15% of patients surviving >5 years
[2]. Consequently, new therapeutic strategies, such as
gene therapy, are being tested in preclinical and clinical
settings. Knowing that apoptosis is a key mechanism
in the regulation of tissue homeostasis, several members
of the tumor necrosis factor (TNF) superfamily have
been implicated in the process. TNF-related apoptosis-
inducing ligand (TRAIL), also known as Apo2L, was
originally identified through its homology to TNF, FasL,
and other members of the TNF superfamily [3,4]. Like
most other members of the TNF superfamily of ligands,
TRAIL is primarily expressed as a type II membrane
protein of 33-35 kD [5]. To date, four human mem-
brane-bound receptors for TRAIL have been identified:
DR4/TRAIL-R1, DR5/TRAIL-R2/KILLER, TRID/DcR1/
TRAIL-R3, and DcR2/TRAIL-R4. Two of the membrane
receptors, DR4 and DR5, contain the essential cytoplas-
mic death domain through which TRAIL can transmit
an apoptotic signal. DcR1 and DcR2 can also bind
TRAIL, but they appear to act as antagonistic receptors
because they lack a functional death domain [6-9].
There are several reasons why TRAIL is of interest for
people working on cancer gene therapy. TRAIL is
unique in that it selectively induces apoptosis in tumor
and transformed cells, but does not harm normal cells
[10,11]. In addition, apoptosis induction in response to
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tumor supressor p53 gene [12]. Because of the inactiva-
tion of p53 in more than 50% of human cancers during
tumorigenesis, the tumors eventually display resistance
to both radiotherapy and chemotherapy. TRAIL, how-
ever, can induce p53-independent apoptosis of cancer
cells [13]. Despite this fact, a significant proportion of
tumor cells display TRAIL resistance by a mechanism
that is not yet fully understood [14,15]. Resistance to
TRAIL-induced apoptosis, both in normal and cancer
cells, was initially considered to be due to DcR1 and/or
DcR2 expression, which compete with DR4 and DR5 for
binding to TRAIL [6,16]. Apart from TRAIL receptor
composition, [17,18] there are a number of other possible
reasons why some cancer cells exhibit TRAIL resistance.
For example, the presence of intracellular apoptosis inhi-
bitory proteins (Bcl-xL, c-FLIP, cIAP etc.) or the loss of
Bax and Bak function may lead to a TRAIL-resistant phe-
notype [14,19]. Interestingly, the engagement of DR4,
DR5, and DcR2 can activate the NF-B pathway [20,21],
and high levels of endogenous NF-B activity interfere
with TRAIL-induced apoptosis. Thus, targeting the
NF-B signaling pathway may help sensitize cancer cells
to TRAIL. In this study, a complementary gene therapy
modality using adenovirus-mediated delivery of an
IKKbΚAm u t a n t( A d I K K bKA) was deployed to test the
extent to which NF-B inhibition sensitized lung cancer
cells to TRAIL (Ad5hTRAIL).
Methods
Adenovirus Preparation
Recombinant adenoviral vectors, AdEGFP [22], Ad5h-
TRAIL [23], AdIKKbKA [24], AdNFBLuc [25], and
AdCMVLacZ [26,27], were amplified in 293 cells and
purified by cesium chloride gradient. After vector purifi-
cation, adenoviral vectors were kept at -80°C in 10 mM
Tris containing 20% glycerol. The titers of purified ade-
noviral stocks were measured to be 10
13 DNA particles/
ml. AdIKKbKA encodes the dominant negative mutant
form (K44A) of IKKb and forms inactive IKK complex
so that IKKb does not phosphorylate IkB. IkBaSR pro-
duces dominant negative mutant form (S32A/S36A) of
IkBa. Thus, the IKK complex cannot phosphorylate
mutant IkBa from S32 and S36 residues. By doing so
NF-B is always sequestered in cytoplasm. Both mutant
proteins interfere with NF-B signaling at different
levels of the signaling cascade.
Cell Culture
The human non-small cell lung carcinoma cell line
A549 was obtained from American Type Culture Collec-
tion. Cells were cultured in RPMI 1640 medium supple-
mented with 10% FBS, 2.2 g/l sodium bicarbonate,
1 mM L-glutamine, and 1% penicillin-streptomycin-
amphoterisine mixture (PSA) using Thermo SteriCult
incubators. The study was carried out in accordance
with Declaration of Helsinki and approved by the Akde-
niz University Committee on Ethics.
Adenoviral Infection of Lung Cancer Cells
Cells were cultured and permitted to adhere for at least
24 hr before adding adenovirus vectors. Before the
infection, lung cancer cells were washed with PBS, and
then infected with vectors at increasing multiplicity of
infection (MOI). Cells were f i r s tk e p ta t3 7 ° Ci nR P M I
1640 medium without FBS for 2 h. An equal volume of
RPMI 1640 supplemented with 20% FBS was then
added to cells. To measure transduction efficiency, the
percentage of EGFP
+ cells was determined by using
fluorescent microscopy and flow cytometry 48 h after
infection. The cell viability was assessed using Propi-
dium iodide exclusion technique.
Cell Viability Assay
Live/Dead Cellular Viability/Cytotoxicity Kit (Molecular
Probes; Eugene, OR) was used to discriminate live cells
from dead cells. This assay is based on the use of Cal-
sein AM and Ethidium homodimer-1 (EthD-1). Calsein
AM is a fluorogenic substrate for intracellular calsein
esterase. It is modified to a green fluorescent compound
(calsein) by active esterase in live cells with intact mem-
branes. In addition, live cells do not allow EthD-1, a red
fluorescent nucleic acid stain, to enter. However, cells
with damaged membrane uptake the dye and stain posi-
tive. Cellular viability assays were conducted 35 h fol-
lowing the infections.
NF-B Transcription Induction Experiments
A549 cells were infected with AdNFkBLuc construct at
an MOI of 5000 DNA particles/cell to determine the
NF-B activation status. AdNFkBLuc vector carries four
tandem copies of the NF-B binding consensus
sequence fused to a TATA-like promoter from the
HSVTK gene. This vector has also a Luciferase reporter
gene. Luciferase assays were conducted 30 h following
the infection using the Luciferase assay system with
Reporter Lysis Buffer as described by the manufacturer
(Promega, Inc.). Bradford assay was performed to mea-
sure the protein concentration in each sample and these
values have subsequently been used to normalize Rela-
tive Light Units (RLU) against the protein concentration.
Flow Cytometry and Western Blotting
Flow cytometry assays were conducted as described pre-
viously [28]. Monoclonal antibody to TRAIL (human)
(cat. no. ALX-804-296-C100; Alexis Biochemicals) was
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PE) (cat. no. ALX-211-201-C050; Alexis Biochemicals) to
reveal TRAIL expression on the cell surface. For Western
Blotting, protein extracts were prepared 48 hours follow-
ing the infection. Then, 10 μgo fA 5 4 9c e l ll i n ee x t r a c t
was loaded in each lane and IKKbKA protein expression
was detected using an anti-HA peroxidase antibody
(Roche Molecular Diagnostic, Indianapolis, Indiana, US,
Cat. No.11667475001). GAPDH expression was detected
using a GADPH antibody (BIODESIGN International,
Maine, US, Cat No. H86504).
Confirmation of apoptosis induction by Annexin V
staining using flow cytometry
FITC-conjugated human Annexin V (ALX-209-250-
T100) was used to quantitate the number of apoptotic
cells using flow cytometry. Annexin V staining proce-
dure was performed according to manufacturer’sp r o t o -
cols (Alexis Biochemicals).
Caspase Activity Assays
It is well established that carboxyfluorescein-labeled cas-
pase inhibitors can irreversibly bind to active caspases.
Figure 1 Efficient transduction of A549 cells with recombinant adenovirus. A549 cells were infected with increasing MOI of adenovirus
encoding the EGFP reporter gene for 48 h. EGFP positive cells were detected by fluorescent microscopy (Panel A), and then analyzed by flow
cytometry (Panel B). Viral doses applied as MOI values in DNA particles/cell are indicated.
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only specific for the active state of the enzyme and also
it is isoform specific. CaspaTag Caspase Activity Kits
were deployed to selectively monitor caspase activation
following infection with gene therapy vectors. FAM-
DEVD-FMK (S7301) was used to measure caspase 3
activation, and then distinguished caspase positive cells
from caspase negative cells by immune fluorescence
microscopy.
Results
Efficient adenoviral transduction of A549 lung cancer
cells
The efficacy of recombinant adenoviral vector transduc-
tion of A549 lung cancer cells was revealed using an
AdEGFP vector to determine the optimum dose of ade-
novirus needed to conduct gene delivery, which is
mainly influenced by viral preparations. While fluores-
cent microscopy was used to follow protein expression,
the transduction efficiency was quantitatively analyzed
using flow cytometry 48 h following the infection.
Almost 100% of the cells were efficiently transduced
with AdEGFP at MOI of 5,000 DNA particles/cell 48 h
after infection (Figure 1).
A549 lung cancer cells are resistant to adenoviral delivery
of hTRAIL or IKKbKA expression
Despite the fact that TRAIL can potently induce tumor
cell apoptosis, TRAIL resistance observed in some
cancer cells critically challenges the use of TRAIL as a
gene therapy agent. To determine the extent to which
A549 lung cancer cells were susceptible to TRAIL, we
infected A549 cells with an adenovirus vectors encoding
hTRAIL (Ad5hTRAIL) or LacZ (AdCMVLacZ, negative
control) at increasing doses and measured cellular viabi-
lity following the infection. As expected, AdCMVLacZ
infection alone did not reduce the number of viable
cells significantly (data not shown). A549 lung cancer
cells were also completely resistant to cytotoxic effects
of hTRAIL, despite the high doses of Ad5hTRAIL (MOI of
10,000 DNA particles/cell) used for the infection (Figure 2,
upper panels).
Increased IKK activity [29,30] and/or NF-B activity
[22] is a major regulatory obstacle against death ligand-
induced cytotoxicity in various tumors. Consequently,
cell survival mediated through the effect of IKK inhibi-
tion, and thereby NF-kB down-regulation, was tested
after A549 infection with AdIKKbKA. As shown in Fig-
ure 2 (lower panels), no decrease in cell viability was
observed even at MOI of 10,000 DNA particles/cell of
AdIKKbKA vector. These results suggested that IKK
inhibition alone does not affect the viability of A549
lung cancer cells.
To rule out the possibility that the lack of any cytotoxic
effect was due to little/no TRAIL expression from the
vector, flow cytometric analysis was performed on A549
cells infected with Ad5hTRAIL. This assay demonstrated
that significant TRAIL overexpression was achieved after
Figure 2 The viability of A549 lung cancer cells is not affected by Ad5hTRAIL or AdIKKbKA infection alone. A549 cells were infected
either by Ad5hTRAIL (Upper Panels) or AdIKKbKA virus (Lower Panels) at increasing doses. Molecular Probe’s Live and Death Cellular Viability and
Toxicity Kit was used to detect viable cells 48 h following the infection, as described in Materials and Methods. The applied viral doses as MOI
values in DNA particles/cell are indicated.
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Page 4 of 11A549 infection with Ad5hTRAIL (Figure 3A). Similarly,
immunoblot analysis was employed to demonstrate
IKKbKA expression. IKKbKA expression was detectable
only when cells were infected with AdIKKbKA vector but
not with AdCMVLacZ (Figure 3B).
NF-B blocking via IKK inhibition sensitizes A549 lung
cancer cells to TRAIL-induced apoptosis
Previous studies by our group have shown that
A549 lung cancer cells can be sensitized to TNF by
AdIKKbKA [22,24] or AdIkBaSR [26,31] expression.
Since A549 cells are also resistant to TRAIL-induced
apoptosis, we tested the extent to which NF-Bi n h i b i -
tion through IKK targetting could sensitize A549 cells
to TRAIL. Thus, A549 cells were co-infected with
Ad5hTRAIL (5000 particles/cell) and AdIKKbKA at
increasing doses, and the percentage of viable cells was
measured 48 h after infection. Over 75% cell death was
observed when A549 cells were co-infected with Ad5h-
TRAIL and at least 5000 MOI AdIKKbKA (Figure 4). In
contrast, AdCMVLacZ co-infection did not sensitize
A549 cells to TRAIL. Together, these findings demon-
strate that IKKbKA expression can overcome TRAIL
resistance in A549 lung cells. We then tested the extent
Figure 3 Ad5hTRAIL and AdIKKbKA transductions of lung cancer cells. Panel A represents a flow cytometry analysis of hTRAIL expression in
A549 cell line. Conditions for infections are as follows: 1, unstained; 2, uninfected (secondary antibody alone); 3, AdLacZ; 4, Ad5hTRAIL (5,000
MOI); 5, Ad5hTRAIL (10,000 MOI). Panel B shows a Western Blotting indicating IKKbKA expression. Adenoviral constructs used in the infections are
indicated above each lane (duplicate independent A549 samples are shown). Molecular standard markers (b galactosidase, 121 kD; and bovine
serum albumin, 70 kD) are provided to the left of the blot.
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vector in sensitizing A549 cells to Ad5hTRAIL. NF-B
inhibition via AdIkBaSR infection also resulted in some
degree of cell death from TRAIL, but the degree of sen-
sitization was less than that of AdIKKbKA delivery (data
n o ts h o w n )s u g g e s t i n gA d I K K bKA inhibition of NF-B
inhibition is more efficient.
Endogenous NF-B activity in A549 cells is upregulated
after Ad5hTRAIL infection but down regulated with
IKKbKA expression
Intracellular NF-B activation is crucial for a variety of
cellular functions. With respect to death ligand-induced
apoptosis, high levels of NF-B activity are associated with
resistance in cancer cells [22]. In addition, signaling
through DR4, DR5 [15,20], and DcR2 [8] can activate NF-
B. Thus, determining the endogenous and TRAIL-
induced NF-B activity of cancer cells before initiation of
TRAIL-based therapy is important. To evaluate the extent
of NF-B activation in A549 cells, we used a recombinant
adenovirus vector encoding an NF-B driven Luciferase
reporter gene (AdNFkBLuc). Luciferase expression was
measured 30 h after infection. As shown in Figure 5, sig-
nificant NF-B activation was achieved after Ad5hTRAIL
infection. Triple infection with AdNFkBLuc, Ad5hTRAIL
and AdIKKbKA or AdCMVLacZ was then performed to
Figure 4 Induction of cell death in A549 cells co-infected with AdIKKbKA and AdhTRAIL. A549 lung cancer cells were co-infected with a
constant dose of Ad5hTRAIL (5,000 MOI; as shown below each panel) and increasing doses of AdIKKbKA (as shown above each panel). Cell
viability was then measured using Molecular Probe’s Live and Death Cellular Viability and Toxicity Kit 48 h following infection. Panel A depicts
fluorescent micrographs of such an infection. By comparison, the quantitative analysis of cell viability is provided in Panel B. Values represent the
mean (± SEM) of three different experiments (n = 6). *p < 0.05.
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activation. Both endogenous and TRAIL-induced NF-B
activity was drastically reduced after infection with
AdIKKbKA. Conversely, AdCMVLacZ infection did not
inhibit endogenous or TRAIL-induced NF-Ba c t i v i t y .
Ad5hTRAIL infection with NF-B inhibition induces
apoptosis in A549 cells
To prove that the mechanism of cell death in A549 cells
following Ad5hTRAIL infection during IKK inhibition
was apoptotic in nature, Annexin V staining was per-
formed. A549 cells were infected with either Ad5hTRAIL
or AdIKKbKA alone, or in combination, and apoptotic
cell death was quantified 48 h following infection. There
was a minimal increase in Annexin V staining on
Ad5hTRAIL or AdIKKbKA infected cells (Figure 6A),
but Ad5hTRAIL and AdIKKbKA coinfection resulted in
a significant increase in Annexin V staining (Figure 6B).
As expected, Ad5hTRAIL and AdCMVLacZ co-infection
did not generate such an effect. To further demonstrate
that apoptosis is the mechanism of cell death in A549
cell line, caspase activation assays were performed follow-
ing coinfection of cells with Ad5hTRAIL and AdIKKbKA
vectors. There was significantly increased Caspase 3
activity detected only when the A549 cells were infected
with Ad5hTRAIL and AdIKKbKA (Figure 7).
Discussion
TRAIL induces apoptosis in a wide range of malignant
cells and has been heavily investigated as a potential ther-
apeutic agent for the treatment of many tumors. These
expectations were largely based on the selective apopto-
sis-inducing properties of TRAIL for cancer cells [32-34].
Contrary to these initial expectations, many cancer cell
lines were subsequently found to be resistant to TRAIL-
induced apoptosis. Consequently, a significant number of
studies have been conducted to understand the molecular
mechanism of TRAIL resistance in cancer cells, so this
barrier could be overcome. In cancer cases where high
decoy receptor expression could potentially contribute to
the resistance to TRAIL, siRNA approaches have been
successfully used to overcome TRAIL resistance in can-
cer cells, as demonstrated for breast [18], lung [28], and
prostate [17] cancer cells.
Based on our previous findings and those by other
groups, the NF-B signaling pathway appeared to be
one of the main molecular mechanisms responsible for
the generation of TRAIL resistance in cancer cells.
Overactive NF-B activity has been implicated in many
aspects of tumor formation and progression, including
the inhibition of apoptosis and enhancing the expression
of antiapoptotic factors [35]. NF-B normally resides in
the cytoplasm as an inactive complex with an inhibitory
Figure 5 NF-B activity is upregulated with Ad5hTRAIL infection but down-regulated with AdIKKbKA in A549 cells. A549 cells were
simultaneously infected with AdNFkBLuc, Ad5hTRAIL, and increasing doses of AdIKKbKA construct for 30 h. As a negative control, AdCMVLacZ
infection was utilized. The different constructs used in the infection and the MOI values represented in DNA particles/cell are listed on the X-axis.
Luciferase activity expressed as Relative Light Units per microgram protein is depicted on the Y-axis, where the values represent the mean (±
SEM) of six independent data points (n = 6). * p < 0.05.
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Page 7 of 11Figure 6 Blocking IKK activity results in TRAIL-induced apoptosis in A549 cells. FITC-conjugated Annexin V and Propidium Iodide (PI)
staining were utilized as apoptosis indicators following infection of A549 lung cancer cells with various combinations of adenovirus constructs
as stated. 10
4 A549 lung cancer cells were gated for each histogram. Histograms are depicted in two different panels for clarity. AdIKKbKA and
Ad5hTRAIL constructs were used in 5,000 DNA particles/cell unless stated otherwise. AdCMVLacZ construct was used at an MOI of 10,000 DNA
particles/cell. Uninfected but FITC-Annexin V and PI stained A549 lung cancer cells were used as controls (gray line).
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Page 8 of 11IB subunit. Upon activation, IB becomes phosphory-
lated by specific kinases (IB kinase, IKK), ubiquinated,
and then degraded. This inactivation of IBe n a b l e st h e
translocation of NF-B into the nucleus, where it can
bind to the promoter region of many genes and activate
their transcription [36]. IKKb is one of the catalytic
domains of the kinase IKK and is essential for NF-B
activation. Thus, inhibition of IKKb may be a particu-
larly useful strategy to specifically interfere with NF-B
activity [24]. Previously, IKK targeting strategy has been
successfully applied to sensitize neuroblastoma [37]
and prostate cancer cells [38] to TRAIL. Although, exo-
genous expression of a dominant negative mutant form
of IKKb sensitized lung cancer cells to TNF by way of
NF-B inhibition, it was unknown whether this approach
would similarly sensitize lung cancer cells to TRAIL.
Thus, in this study we tested a complementary gene ther-
apy modality involving IKK inhibition to overcome
TRAIL resistance. In the present study, we demonstrated
that inhibition of the NF-B signaling pathway, by way of
IKKbKA expression, sensitized A549 cells to TRAIL-
induced apoptosis. In accordance with this, the recently
identificed TRAIL receptor-binding protein, protein argi-
nine methyltransferase 5 (PRMT5) [39], was found to
potentiate TRAIL-induced NF-Ba c t i v a t i o nt h r o u g h
IKK leading to induction of several NF-B target genes.
Interestingly, PRMT5 gene silencing sensitized various
cancer cells to TRAIL. These data suggest that PRMT5
expression helped to maintain TRAIL resistance through
NF-B activation involving IKK complex in cancer cells.
Conclusions
The IKK complex may be a good target to specifically
interfere with NF-B activation in TRAIL-resistant can-
cer cells, such that gene therapy strategies involving
exogenous TRAIL expression with concurrent inhibition
of the NF-B pathway through IKK modulation of func-
tion may extend the therapeutic index of TRAIL for
patients with lung cancer.
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Figure 7 Inhibition of IKK activity induces TRAIL-mediated Caspase 3 activation in lung cancer cells. Caspase activity assays were
performed following co-infection of A549 lung cancer cells with Ad5hTRAIL and AdIKKbKA or AdCMVLacZ vectors. MOI and types of viral
vectors used in the infection are provided on the X-axis. AdCMVLacZ construct was used at an MOI of 10,000 DNA particles/cell. Caspase activity
was assessed under fluorescent microscopy. Data represent the mean of (±SEM) fıve independent data points. *p < 0.05.
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